 he companys lead product candidate is Ensifentrine, an inhaled PDE3, and PDE4 inhibitor, which is being developed as a maintenance treatment for chronic obstructive respiratory disease. The stock is trading at a 75 discount to its high after successful Phase 2b data for Ensifentrine as a maintenance treatment for chronic obstructive respiratory disease. 